Considering the role of HER3 in the development and progression of HER2+ breast cancer and our preliminary data suggesting that loss of miR-205 might promote HER2-driven tumorigenesis, it is not surprising that low expression of this miRNA is a feature of HER2+ breast cancer, as also reported in series of human tumors [16]. This evidence concerns the gene ERBB2 and breast carcinoma.